Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533388 | 0.88 | DPP4 (0.47) | DPP4 | |
| SCHEMBL15533200 | 0.86 | DPP4 (0.42) | DPP4KCNH2 | |
| SCHEMBL15533174 | 0.80 | DPP4 (0.53) | DPP4KCNH2 | |
| SCHEMBL160189 | 0.79 | DPP4 (0.53) | DPP4KCNH2 | |
| SCHEMBL15516850 | 0.79 | DPP4 (0.53) | DPP4KCNH2 | |
| SCHEMBL24743941 | 0.76 | DPP4 (0.51) | DPP4KCNH2 | |
| SCHEMBL15091721 | 0.75 | DPP4 (0.34) | DPP4 | |
| SCHEMBL20528287 | 0.74 | DPP4 (0.51) | DPP4 | |
| SCHEMBL12047552 | 0.70 | DPP4 (0.79) | DPP4KCNH2 | |
| SCHEMBL12047731 | 0.70 | DPP4 (0.68) | DPP4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3125882-A2 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2017-02-08 | — | — | EP | disclosed |
| EP-3096765-A1 | TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2016-11-30 | — | — | EP | disclosed |
| EP-3082829-A1 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2016-10-26 | — | — | EP | disclosed |
| EP-2981269-A1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2016-02-10 | — | — | EP | disclosed |
| WO-2015150299-A2 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015110402-A1 | TREATMENT OF METABOLIC DISORDERS IN CANINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2015-07-30 | — | — | WO | disclosed |
| WO-2015091313-A1 | TREATMENT OF METABOLIC DISORDERS IN FELINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2015-06-25 | — | — | WO | disclosed |
| EP-2854824-A1 | USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2015-04-08 | — | — | EP | disclosed |
| WO-2014161836-A1 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2014-10-09 | — | — | WO | disclosed |
| WO-2013174769-A1 | USE OF KERATINOCYTES AS A BIOLOGICALLY ACTIVE SUBSTANCE IN THE TREATMENT OF WOUNDS, SUCH AS DIABETIC WOUNDS, OPTIONALLY IN COMBINATION WITH A DPP-4 INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-28 | — | — | WO | disclosed |